Franklin Resources Inc. Trims Stock Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Franklin Resources Inc. cut its holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 21.7% in the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,342,500 shares of the company's stock after selling 371,996 shares during the quarter. Franklin Resources Inc. owned about 1.32% of Dyne Therapeutics worth $44,719,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. AQR Capital Management LLC grew its stake in Dyne Therapeutics by 4.3% during the 2nd quarter. AQR Capital Management LLC now owns 8,495 shares of the company's stock valued at $300,000 after purchasing an additional 352 shares during the last quarter. Nisa Investment Advisors LLC lifted its holdings in shares of Dyne Therapeutics by 904.1% during the second quarter. Nisa Investment Advisors LLC now owns 743 shares of the company's stock worth $26,000 after purchasing an additional 669 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in Dyne Therapeutics by 24.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,631 shares of the company's stock valued at $123,000 after buying an additional 709 shares during the last quarter. KBC Group NV increased its holdings in Dyne Therapeutics by 53.4% in the 3rd quarter. KBC Group NV now owns 2,157 shares of the company's stock worth $77,000 after buying an additional 751 shares during the period. Finally, Amalgamated Bank raised its position in Dyne Therapeutics by 39.9% during the 2nd quarter. Amalgamated Bank now owns 2,792 shares of the company's stock worth $99,000 after buying an additional 796 shares during the last quarter. Institutional investors and hedge funds own 96.68% of the company's stock.

Analysts Set New Price Targets

DYN has been the topic of several recent research reports. Oppenheimer reaffirmed an "outperform" rating and issued a $55.00 price objective on shares of Dyne Therapeutics in a report on Tuesday, September 3rd. HC Wainwright reaffirmed a "buy" rating and issued a $55.00 price target on shares of Dyne Therapeutics in a report on Wednesday, November 13th. Robert W. Baird started coverage on Dyne Therapeutics in a research note on Friday, December 13th. They set an "outperform" rating and a $46.00 price objective for the company. Chardan Capital restated a "buy" rating and issued a $50.00 target price on shares of Dyne Therapeutics in a research note on Wednesday, November 13th. Finally, Baird R W upgraded Dyne Therapeutics to a "strong-buy" rating in a research report on Thursday, December 12th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $50.42.

Insider Activity at Dyne Therapeutics

In other Dyne Therapeutics news, Director Jason P. Rhodes sold 782 shares of Dyne Therapeutics stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $33.10, for a total value of $25,884.20. Following the sale, the director now owns 15,962 shares in the company, valued at $528,342.20. The trade was a 4.67 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Dirk Kersten sold 79,411 shares of the business's stock in a transaction dated Friday, September 20th. The shares were sold at an average price of $36.45, for a total transaction of $2,894,530.95. Following the completion of the sale, the director now owns 234,127 shares in the company, valued at approximately $8,533,929.15. This trade represents a 25.33 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 167,341 shares of company stock valued at $5,862,564. Corporate insiders own 20.77% of the company's stock.

Dyne Therapeutics Trading Up 0.2 %

DYN stock opened at $26.16 on Wednesday. Dyne Therapeutics, Inc. has a 12-month low of $11.66 and a 12-month high of $47.45. The business's 50-day moving average is $30.14 and its 200 day moving average is $35.19. The stock has a market cap of $2.66 billion, a price-to-earnings ratio of -7.35 and a beta of 1.09.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.25). As a group, equities analysts forecast that Dyne Therapeutics, Inc. will post -3.45 EPS for the current fiscal year.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.